Pfizer Inc. (NYSE:PFE) Stock Position Raised by Aberdeen Wealth Management LLC

Aberdeen Wealth Management LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 2.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,302 shares of the biopharmaceutical company’s stock after acquiring an additional 476 shares during the quarter. Aberdeen Wealth Management LLC’s holdings in Pfizer were worth $588,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PFE. Marshall Wace LLP increased its stake in Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after purchasing an additional 8,378,173 shares in the last quarter. Swedbank AB acquired a new position in shares of Pfizer in the first quarter worth about $172,902,000. International Assets Investment Management LLC purchased a new position in shares of Pfizer in the third quarter worth approximately $146,481,000. 1832 Asset Management L.P. raised its holdings in shares of Pfizer by 24,961.6% during the second quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock valued at $69,891,000 after acquiring an additional 2,487,919 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its position in shares of Pfizer by 120.7% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company’s stock valued at $130,181,000 after acquiring an additional 2,459,666 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on PFE shares. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Stock Performance

PFE stock opened at $24.88 on Tuesday. The company has a market capitalization of $140.97 billion, a price-to-earnings ratio of 33.62, a P/E/G ratio of 0.79 and a beta of 0.67. The firm has a 50 day moving average of $28.55 and a two-hundred day moving average of $28.65. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue was up 31.2% compared to the same quarter last year. During the same period last year, the company earned ($0.17) earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.75%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.